细胞色素P450 与药物代谢的研究现状

摘要/Abstract

摘要： 细胞色素P450(CYP)在众多中西药物代谢中起着非常重要的作用。本文综述了与药物代谢相关的CYP 亚型、CYP 与药物相互作用的关系及中药对CYP 的影响, 旨在合理解释和预测临床上药物间相互作用和药物不良反应等。同时选择适当的药物作为探针来评价CYP 的活性, 为实现临床个体化给药提供科学依据。

关键词: 细胞色素P450, 中药, 药物相互作用, 药物代谢

Abstract: Cytochrome P450 is one of the important drug metabolization enzymes in humans. This paper reviews drug-relevant CYP, the relationship of CYP and drug interaction, and effects of Chinese medicine on CYP. The aim is to answer and predict the clinical drug interaction and the adverse drug reactions. Moreover, suitable drug can be selected to evaluate the action of CYP, and it can offer the scientific assurance for clinical individual therapy.

Key words: cytochrome P450, Chinese medicine, drug interaction, drug metabolism

中图分类号:

R966

朱立勤, 娄建石. 细胞色素P450 与药物代谢的研究现状[J]. 中国临床药理学与治疗学, 2004, 9(10): 1081-1086.

ZHU Li-Qin, LOU Jian-Shi. Resent studies on cytochrome P450 and drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1081-1086.

参考文献

1 Estabrook RW.A passion for P450s(rememberances of the early history of research on cytochrome P450)[J]. Drug Metab Dispos, 2003;31(12):1461-73
2 Kivisto KT, Kroemer HK.Use of probe drugs as predictors of drug metabolism in humans[J]. J Clin Pharmacol, 1997;37 (Suppl 1):40-8
3 Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J]. Eur J Clin Invest, 2003; 33(Suppl 2):23-30
4 Schaeffeler E, SchwabM, Eichelbaum M, Zanger UM.CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR[J]. Hum Mutat, 2003;22(6):476-85
5 Kitada M.Genetic polymorphism of cytochrome P450 enzymes in Asian populations:focus on CYP2D6[J]. Int J Clin Pharmacol Res, 2003;23(1):31-5
6 Charlier C, Broly F, Lhermitte M, Pinto E, AnsseauM, Plomteux G.Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine[J]. Ther Drug Monit, 2003;25(6):738-42
7 Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP).In vivo studies inWistar and Dark Agouti rats as well as in vitro studies in human liver microsomes[J]. Biochem Pharmacol, 2004;67 (2):235-44
8 Matoh N, Tanaka S, Takehashi M, Banasik M, Stedeford T, Masliah E, et al. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells [J]. Gene Expr, 2003;11(3-4):117-24
9 Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline[J]. Hum Psychopharmacol, 2004;19(1):17-23
10 Juan A, Carrillo, Sara I, Ramos, Jose AG. Agundez, et al. Analy sis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A[J]. Ther Drug Monit, 1998;20(3):319-24
11 Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, et al. Effects of cytochrome b(5)on drug oxidation activities of human cytochrome P450 (CYP)3As:similarity of CYP3A5 with CYP3A4 but not CYP3A7[J]. Biochem Pharmacol, 2003; 66(12):2333-40
12 Rosenbrock H, Hagemeyer CE, Ditter M, Knoth R, Volk B. Identification, induction and localization of cytochrome P450s of the 3A-subfamily in mouse brain[J]. Neurotox Res, 2001;3 (4):339-49
13 Torimoto N, Ishii I, HataM, Nakamura H, Imada H, Ariyoshi N, et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4[J]. Biochemistry, 2003;42(51):15068-77
14 Yamamoto T, Suzuki A, Kohno Y.High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method[J]. Xenobiotica, 2004; 34(1):87-101
15 Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J.Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates[J]. Chirality, 2004; 16(2):79-85
16 Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromy cin breath test predicts the clearance of midazolam[J]. Clin Pharmacol Ther, 1995;57(1): 16-24
17 Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB.Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients[J]. Clin Pharmacol Ther, 1992;52(5):471-8
18 Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root)on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004;75(1):89-100
19 Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, et al. The olivacine derivatives 16020 (9-hydroxy-5, 6-dimethyl-N-[2-(dimethylamino)ethyl]-6H-pyrido(4, 3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture [J]. Drug Metab Dispos, 2004; 32(1):80-8
20 Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease[J]. Circulation, 2004;109 (2):178-83
21 Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects[J]. Life Sci, 2004;74(7):827-34
22 Tanaka E, Kurata N, Yasuhara H. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes[J]. J Clin Pharm Ther, 2003;28(6):493-6
23 Spina E, Scordo MG, D' Arrigo C. Metabolic drug interactions with new psychotropic agents[J]. Fundam Clin Pharmacol, 2003;17(5):517-38
24 Benetton S, Kameoka J, Tan A, Wachs T, Craighead H, Henion JD.Chip-based P450 drug metabolism coupled to electrospray ionization-mass spectrometry detection[J]. Anal Chem, 2003;75(23):6430-6
25 Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P.Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function[J]. Clin Pharmacol Ther, 2004;75(1):80-8
26 Van Den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, Schellens JH. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol[J]. Invest New Drugs, 2004;22(2):151-8
27 Van Dijk KN, Plat AW, Van Dijk AA, Piersma-Wichers M, de Vries-Bots AM, Slomp J, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype[J]. Thromb Haemost, 2004; 91 (1):95-101
28 Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J]. Circulation, 2004; 109(2):166-71
29 孙霞, 吴葆杰, 张美.调血脂药物与肌病、横纹肌溶解症[J]. 中国药理学通报, 2003;19(2):130-3
30 王智勇, 彭仁秀, 张志喜.当归醇沉组分对肝CYP 同工酶的影响[J]. 现代中西医结合杂志, 2001; 10(11):1006-7
31 侯艳宁, 朱秀媛, 程桂芳.黄芩甙对小鼠肝细胞色素P450及其亚家族的诱导[J]. 解放军药学学报, 2000; 16(4): 68-71
32 杨秀芬, 王乃平, 曾繁典.中药有效成分对药物代谢酶的影响[J]. 中国中药杂志, 2002; 27(5):325-8
33 侯佩玲, 乔晋萍, 张瑞萍, 崔立杰, 再帕尔.阿不力孜, 等. 菊花提取物对大鼠肝微粒体细胞色素P450 的影响[J]. 中医药学报, 2003; 31(3):47-8
34 程泽能, 李焕德.化学药物与中药相关的相互作用[J]. 中国临床药理学杂志, 2002;18(1):74-7
35 Ueng YF, Kuo YH, Wang SY, Lin YL, Chen CF.Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL 6J but not in DBA 2J mice[J]. Life Sci, 2004;74(7):885-96
36 Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root)on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004;75(1):89-100
37 Le Bon AM, Vernevaut MF, Guenot L, Kahane R, Auger J, Arnault I, et al. Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats[J]. J Agric Food Chem, 2003;51(26):7617-23

[1]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[2]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.
[3]	胡康一, 曹林忠, 万超超, 尚征亚, 杨小瑞, 张勇杰. 基于线粒体功能障碍探讨中药防治激素性股骨头坏死的基础研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 688-696.
[4]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[5]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[6]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[7]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[8]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[9]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[10]	陈升富, 李晓琳, 王维刚, 杜玮泽, 李茂星. 中药解热作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 334-344.
[11]	王文娟, 齐鸣瑞, 田利民. Nrf2在糖尿病心肌病中的作用及中药干预研究进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1163-1170.
[12]	刘璐, 陈笑艳. 国产小分子化学创新药临床药物相互作用研究现状[J]. 中国临床药理学与治疗学, 2021, 26(8): 863-875.
[13]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[14]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[15]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.